PHATPhathom Pharmaceuticals, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−46% vs 200-day) and heavily shorted (+12% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −46% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How PHAT is trading
Phathom Pharmaceuticals, Inc. is −58% over the past year while the S&P 500 is +16%: 74 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −46%
vs 200-day average · a clear downtrend
- RSI (14)
- 37
RSI (14) · neutral
- Below its 52-week high
- 68%
Below its 52-week high
Details›
- Last close2026-10-23
- $5.72
- 1 monthS&P 500 −0.94%
- −19%
- 1 yearS&P 500 +16%
- −58%
- 5 yearsS&P 500 +86%
- −82%
- vs 50-day average$7.96
- −28%
- 52-week high
- $18.08
- 52-week low
- $5.72
- Annualised volatility
- 107%
| Year | Return |
|---|---|
| 2026 (year to date) | −66% |
| 2025 | +104% |
| 2024 | −11% |
| 2023 | −19% |
| 2022 | −43% |
| 2021 | −41% |
| 2020 | +6.7% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | −8.0% |
| Feb | 7 | 4 of 7 | +6.6% |
| Mar | 7 | 1 of 7 | −12% |
| Apr | 7 | 4 of 7 | +4.7% |
| May | 7 | 3 of 7 | −4.1% |
| Jun | 7 | 5 of 7 | +23% |
| Jul | 7 | 4 of 7 | −0.43% |
| Aug | 7 | 5 of 7 | +14% |
| Sep | 7 | 2 of 7 | −3.7% |
| Oct | 7 | 2 of 7 | −6.6% |
| Nov | 7 | 3 of 7 | −10% |
| Dec | 7 | 5 of 7 | +7.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.
Biotechnology
Ranks #161 of 194 by RyuScore